Professor | Jing Yang | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Jing Yang
Contact Information	jingy@tongji.edu.cn
Language ability	Chinese, English
Province	Shanghai

Upload Avatar (500 x 500)

Name

Jing Yang

Contact Information

jingy@tongji.edu.cn

Language ability

Chinese, English

Province

Shanghai

University/Lab Affiliation and Title	Tongji University
Faculty	Life Sciences
Academic Background & Achievements	2009 - Bachelor of Science: Shandong University 2015 - Doctor of Science: Shanghai Pasteur Institute, Chinese Academy of Sciences Identified several pathogenic protein degradation targets DUB/E3 during doctoral studies
Work Experience	2015-2020 - Dana-Farber Cancer Institute, Harvard Medical School: Postdoctoral Training 2021 Jan-Aug - Hefei Institutes of Physical Science, Chinese Academy of Sciences: Associate Researcher 2022 Sep-Present - Tongji University, School of Life Sciences and Technology: Distinguished Researcher

University/Lab Affiliation and Title

Tongji University

Faculty

Life Sciences

Academic Background & Achievements

2009 - Bachelor of Science: Shandong University
2015 - Doctor of Science: Shanghai Pasteur Institute, Chinese Academy of Sciences
Identified several pathogenic protein degradation targets DUB/E3 during doctoral studies

Work Experience

2015-2020 - Dana-Farber Cancer Institute, Harvard Medical School: Postdoctoral Training
2021 Jan-Aug - Hefei Institutes of Physical Science, Chinese Academy of Sciences: Associate Researcher
2022 Sep-Present - Tongji University, School of Life Sciences and Technology: Distinguished Researcher

Areas of Focus	Targeted and immunotherapy for malignant diseases such as leukemia Discovery and development of first-in-class targeted degraders
Publications	Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-COV-2, Jing Yang et al., 2023 Gilteritinib: Repurposing of AXL-targeting kinase inhibitors against COVID-19, Jing Yang et al., 2023 Discovery of IHMT-337 as a potent irreversible inhibitor targeting novel noncanonical role of EZH2 for triple-negative breast cancer, Jing Yang et al., 2023 Inhibition of deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2, Jing Yang et al., 2022 Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2, Jing Yang et al., 2022 The deubiquitinase USP44 promotes Treg function during inflammation by preventing FOXP3 degradation, Jing Yang et al., 2020 Inhibition of the deubiquitinase USP10 induces degradation of SYK, Jing Yang et al., 2020 HSP70 and FLT3-ITD: targeting chaperone system to overcome drug resistance, Jing Yang et al., 2021 Ubiquitin-Specific Protease 4 Promotes Th17 Cell Function under Inflammation by Deubiquitinating and Stabilizing RORγt, Jing Yang et al., 2015 TRAF5 Mediated K63-linked Polyubiquitination Plays an Essential Role in the Positive regulation of RORγt on promoting IL-17A Expression, Jing Yang et al., 2015 The E3 deubiquitinase USP17 is a positive regulator of retinoic acid-related orphan nuclear receptor γt (RORγt) in Th17 cells, Jing Yang et al., 2014

Areas of Focus

Targeted and immunotherapy for malignant diseases such as leukemia
Discovery and development of first-in-class targeted degraders

Publications

Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-COV-2, Jing Yang et al., 2023
Gilteritinib: Repurposing of AXL-targeting kinase inhibitors against COVID-19, Jing Yang et al., 2023
Discovery of IHMT-337 as a potent irreversible inhibitor targeting novel noncanonical role of EZH2 for triple-negative breast cancer, Jing Yang et al., 2023
Inhibition of deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2, Jing Yang et al., 2022
Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2, Jing Yang et al., 2022
The deubiquitinase USP44 promotes Treg function during inflammation by preventing FOXP3 degradation, Jing Yang et al., 2020
Inhibition of the deubiquitinase USP10 induces degradation of SYK, Jing Yang et al., 2020
HSP70 and FLT3-ITD: targeting chaperone system to overcome drug resistance, Jing Yang et al., 2021
Ubiquitin-Specific Protease 4 Promotes Th17 Cell Function under Inflammation by Deubiquitinating and Stabilizing RORγt, Jing Yang et al., 2015
TRAF5 Mediated K63-linked Polyubiquitination Plays an Essential Role in the Positive regulation of RORγt on promoting IL-17A Expression, Jing Yang et al., 2015
The E3 deubiquitinase USP17 is a positive regulator of retinoic acid-related orphan nuclear receptor γt (RORγt) in Th17 cells, Jing Yang et al., 2014

Leukemia Malignant Diseases Targeted Therapy Immunotherapy Protein Degradation Dub E3 Ligases Drug Discovery Resistance Mechanisms Clinical Development

Ang Li - Tongji University

Min Qian - East China Normal University

Jing Yang - Tongji University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us